Connor Hayes

Former buy-side research background. Following US equities, tech-driven trends, and capital flow dynamics. Sharing market observations regularly.

[Connor Hayes @409285]

The next few weeks matter for $CELC.
Priority Review and the July PDUFA keep the catalyst alive, but the tape still needs to prove this is accumulation, not just event chasing.

[Agent007 @Agent0088156721]

$CELC 6mos. Tried to push up into the gap last week. Key weeks heading into the PDUFA with a gap to phil. Let's if she builds upon these TAs showing some life.

[Connor Hayes @409285]

Biotech weekend mood:
“Just one FDA date, how stressful can it be?”

Famous last words.

$CELC has a real catalyst, but I’m not pretending event trades are gentle.

[Connor Hayes @409285]

$CELC stalls right at the critical $100 mark.

I see traders positioning around gedatolisib as the FDA clock gets closer.

This is not a normal momentum tape; it is approval-risk pricing.

I want 100 to hold with real volume, not just a print.

Do you trust the setup?

[Connor Hayes @409285]

What’s single-handedly propping up $CELC’s rebound?

I see buyers trying to hold the rebound near 95 to 100 while the tape favors selective risk.

The FDA/PDUFA setup keeps attention on the stock, but biotech needs follow-through.

I want 100 reclaimed.

Early money or short pop?

[Connor Hayes @409285]

$CELC bounced 6%+. Is that demand or just biotech hope?

Liquidity still has to answer.

Gedatolisib/FDA optimism came back, price closed near 96, but post-market faded and volume stayed below average.

I’m watching whether 95 becomes real demand.

Show the defended level.

[Connor Hayes @409285]

@jayg327 Fair take. $CELC feels like one of those names where the thesis hasn’t broken, but the market is demanding final OS confirmation before giving it real credit.

[Connor Hayes @409285]

$CELC is the kind of stock that exposes boredom 👀

No headline.

No clean breakout.

No obvious reason to act.

Yet people still click.

Sometimes traders don't need opportunity.

They just need something to do.

That's expensive.

#CELC #Biotech #Overtrading

[Connor Hayes @409285]

$CELC volume: 2.13M Friday 👀

For the first time this week — above average.

No news announced. But the chart had a spike down then bounce.

When volume returns after silence, something shifted.
Watch Monday open carefully.

#CELC #Observation #Biotech

[Connor Hayes @409285]

$CELC dropped to $82 intraday. Bounced to $86. Closed -2.24% 👀

No news. No announcement.

Volume: 744K vs. avg 1.57M.

The moves that hurt most come without a press release.

#CELC #Observation #Biotech

[Connor Hayes @409285]

$CELC drifting lower on near-zero volume today 👀

200K shares. Average: 1.54 million.

No news. No reaction. Just quiet erosion.

Biotech retail holders live or die on news flow — silence is their biggest enemy.

Right now, that's all there is.

#CELC #Observation #Biotech

[Connor Hayes @409285]

$CELC had FDA pathway news six days ago 👀

Many saw it as a clear positive signal.

The stock is still flat.

Good news doesn't always equal immediate return.

Reading direction and reading timing are different skills.

#CELC #Observation #Biotech

[Connor Hayes @409285]

Market rallied broadly. $CELC still closed red 👀
Day4: good stories ≠ good trades.

Day7: risk-on doesn't lift every boat.

DM「Week4」 for free Week4 recap. No charge.

#CELC #Observation #Biotech #Week4

[Connor Hayes @409285]

$CELC is down 36% from May highs 👀

The analysts loudest in April went quiet.

That silence tells you more than the original thesis did.

Watch what people stop saying.

#CELC #Observation #Week4

[Connor Hayes @409285]

$CELC continued drifting below support 👀

Not because the science failed.

Because expectations had already run ahead of reality.

Markets price forward. When the future arrives, it's often already settled.

#CELC #Observation #Biotech

[Connor Hayes @409285]

Positive developments don't always create positive returns 👀
Many investors discover that lesson through biotech.
$CELC offers another reminder.
#CELC #Observation

[Connor Hayes @409285]

$CELC received plenty of attention after recent developments 👀
What matters isn't who saw the news.
It's how capital reacted once the news became widely accepted.
#CELC #Observation #Biotech

[Connor Hayes @409285]

$CELC attracted attention after major headlines 👀
Attention alone doesn't create lasting demand.
That's where many investors get trapped.
#CELC #Observation #Biotech

[Connor Hayes @409285]

$CELC attracted attention after major news 👀
What many investors watched was price.
What mattered more was participation.
#CELC #Observation #Biotech

[Connor Hayes @409285]

$CELC spent another week showing how quickly biotech sentiment can change 👀
Clinical headlines attracted attention.
Sustained buying never fully arrived.
The market remained skeptical.
#CELC #Observation #Biotech

[Connor Hayes @409285]

$CELC struggles badly to win back investor trust 👀
Lots of casual eyes follow it, but no serious capital wants to commit.
#CELC #Observation #Biotech
Series done | Follow, handpicked quality biotech to skip hype traps #7DaySeriesWrap